Concepedia

Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation

Eman S. Nossier, Rania A. Alasfoury, Mohamed Hagras, May A. El‐Manawaty, Sara M. Sayed, Ibrahim M. Ibrahim, Hazem Elkady, Ibrahim H. Eissa, Heba S. A. Elzahabi

Journal of Molecular Structure · 2022 · 25 citations · 49 references

DOI

Concepts

References

49

GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

M Abraham, Teemu J. Murtola, Roland Schulz et al. · SoftwareX · 2015 · 26.8K citations · Full text

, , +11

Rational design of inhibitors that bind to inactive kinase conformations

Yi Liu, Nathanael S. Gray · Nature Chemical Biology · 2006 · 1.1K citations · Full text

, , +14

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 627 citations · Full text

, , +17

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

, , +16

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Jin H. Park, Yingting Liu, Mark A. Lemmon et al. · Biochemical Journal · 2012 · 403 citations · Full text

, , +17